Company news
Recce Pharmaceuticals Ltd. (ASX:RCE) news
Recce Pharmaceuticals Ltd. news releases on 6ix. Latest, Aug 31, 2026: Appendix 4E and FY26 Annual Report
Press releases & updates
Appendix 4E and FY26 Annual Report
August 31, 2026
HREC Approves Comparator Study for Pivotal Phase 3 DFI
August 18, 2026
Vietnamese Patent Granted for RECCE Anti-Infectives
July 13, 2026
AUD $3.7M Income Tax Refund Received
June 30, 2026
Placement & SPP to raise $8 million
June 25, 2026
HREC Approval Accelerates Global Phase 3 DFI Strategy
June 21, 2026
Addendum to Recce Signs Middle East Licensing Term Sheet
May 27, 2026
Recce Signs Middle East Licensing Term Sheet
May 26, 2026
Brazil Patent Granted for RECCE Anti-Infectives
March 24, 2026
RCE Investor Webinar Presentation Deck
March 19, 2026
Appendix 4D and Interim Financial Report
February 27, 2026
Recce Enters Second U.S. Department of Defense R&D Agreement
February 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 30, 2026
AUD $5.3m R&D Rebate Received
January 13, 2026
RCE Awarded Advanced Overseas Finding up to A$85m
December 15, 2025
Hong Kong Patent Granted for RECCE Anti-Infectives
November 26, 2025
Positive Efficacy Data for Inhaled R327 in HAP/VAP Model
November 25, 2025
Patient Dosing Underway in Ph 3 Indonesia DFI Trial
September 25, 2025
Preliminary Final Report
August 29, 2025
R327G Highly Effective in Burn Wounds Model
August 12, 2025
Recce Signs Debt Facility with Avenue Capital Group
June 17, 2025
Successful Placement of Entitlement Offer Shortfall
June 3, 2025
China Patent Accepted for RECCE Anti-Infectives
May 26, 2025
Recce Enters into USA Department of Defense R&D Agreement
April 27, 2025
Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections
April 23, 2025
Entitlement Offer - Offer Booklet and Access Letter
April 22, 2025
Phase II Clinical Trial Receives Additional Approval for DFI
April 22, 2025
Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
April 10, 2025
Placement and Entitlement Offer to Fund Phase III Trials
April 10, 2025
Key Opinion Leader Presentation
March 2, 2025
Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
February 27, 2025
Japan Patent Allowance for RECCE Anti-Infectives
February 25, 2025
Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
February 19, 2025
Positive Phase II Data from Clinical Trial of R327 Gel
February 16, 2025
Trading Halt
February 13, 2025
Pause in Trading
February 13, 2025
Correction to Appendix 4C and Quarterly Activities Report
February 6, 2025
Patient Dosing Complete in Phase II ABSSSI Trial of R327G
January 20, 2025
Regulatory Approval for Registrational Phase 3 R327G Trial
December 8, 2024
Australia Patent Granted for RECCE Anti-Infectives
November 25, 2024
AUD $6.75m R&D Rebate Approved
November 13, 2024
Ethics Approval for Registrational Ph3 R327G Clinical Trial
November 10, 2024
AGM Presentation
November 5, 2024
Phase II ABSSSI Clinical Trial Advances to Final Stages
November 4, 2024
Efficacy Data & Approval to Continue Ph II ABSSSI Trial
October 27, 2024
Ph II ABSSSI Trial Recruitment and Dosing Passes Halfway
October 8, 2024
Notice of Special General Meeting/Proxy Form
October 8, 2024
Recce Pharmaceuticals Announces Successful Completion of Share Purchase Plan
August 6, 2024
Successful Completion of Share Purchase Plan
August 4, 2024
Recce Pharmaceuticals Receives $2 Million Grant from U.S. Department of Defense for RECCE® 327 Gel
July 16, 2024